Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Journal of Clinical Pharmacology|July 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1Hardik Chandasana, Mark Bush, Mounir Ait-Khaled, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2004
Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agentAnthony R White, Clive Kaye, James Poupard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 7, 2014
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of foodStephen Weller, Shuguang Chen, Julie Borland, et al.
Ear, Nose, & Throat Journal|September 27, 2006
Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strainsJack B Anon, Berrylin Ferguson, Monique Twynholm, et al.
Clinical Pharmacology : Advances and Applications|July 2, 2020
The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination TabletRashmi Mehta, Joseph Piscitelli, Allen Wolstenholme, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
AIDS (London, England)|September 11, 2015
Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeksPablo Tebas, Princy Kumar, Charles Hicks, et al.
Nature Nanotechnology|November 6, 2014
Balancing scientific tensionsFern Wickson, Nanna B Hartmann, Rune Hjorth, et al.
European Journal of Clinical Pharmacology|February 23, 2016
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendationIvy Song, Steve Weller, Juhin Patel, et al.
Clinical Pharmacology and Therapeutics|July 17, 2024
Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient CharacteristicsHardik Chandasana, Mark Bush, Cindy Vavro, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacology|July 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1Hardik Chandasana, Mark Bush, Mounir Ait-Khaled, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2004
Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agentAnthony R White, Clive Kaye, James Poupard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 7, 2014
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of foodStephen Weller, Shuguang Chen, Julie Borland, et al.
Ear, Nose, & Throat Journal|September 27, 2006
Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strainsJack B Anon, Berrylin Ferguson, Monique Twynholm, et al.
Clinical Pharmacology : Advances and Applications|July 2, 2020
The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination TabletRashmi Mehta, Joseph Piscitelli, Allen Wolstenholme, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
AIDS (London, England)|September 11, 2015
Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeksPablo Tebas, Princy Kumar, Charles Hicks, et al.
Nature Nanotechnology|November 6, 2014
Balancing scientific tensionsFern Wickson, Nanna B Hartmann, Rune Hjorth, et al.
European Journal of Clinical Pharmacology|February 23, 2016
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendationIvy Song, Steve Weller, Juhin Patel, et al.
Clinical Pharmacology and Therapeutics|July 17, 2024
Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient CharacteristicsHardik Chandasana, Mark Bush, Cindy Vavro, et al.
Pageof 8